Duvelisib Patent Expiration
Duvelisib is Used for treating chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. It was first introduced by Secura Bio Inc
Duvelisib Patents
Given below is the list of patents protecting Duvelisib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Copiktra | US12213983 | Treatment of cancers using PI3 kinase isoform modulators | Apr 26, 2035 | Secura |
| Copiktra | US8193182 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | Sep 24, 2032 | Secura |
| Copiktra | USRE46621 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | May 17, 2032 | Secura |
| Copiktra | US11312718 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | Jan 10, 2032 | Secura |
| Copiktra | US9840505 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof | Jan 10, 2032 | Secura |
| Copiktra | US9216982 | Certain chemical entities, compositions and methods | Jan 05, 2029 | Secura |
Duvelisib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Duvelisib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
